Repare Therapeutics (RPTX)
(Delayed Data from NSDQ)
$3.20 USD
+0.05 (1.59%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $3.20 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Balance Sheet
Fiscal Year End for Repare Therapeutics Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 224 | 344 | 342 | 334 | 95 |
Receivables | 15 | 4 | 3 | 6 | 3 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 5 | 6 | 6 | 7 | 1 |
Total Current Assets | 244 | 354 | 351 | 347 | 99 |
Net Property & Equipment | 4 | 4 | 6 | 4 | 2 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 2 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 4 | 1 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 1 | 1 | 1 | 1 |
Total Assets | 254 | 364 | 369 | 357 | 103 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 0 | 2 | 2 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 24 | 22 | 19 | 6 | 1 |
Income Taxes Payable | 0 | 1 | 1 | 0 | 0 |
Other Current Liabilities | 10 | 53 | 12 | 2 | 0 |
Total Current Liabilities | 39 | 79 | 35 | 11 | 4 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 2 | 3 | 40 | 56 | 8 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 42 | 85 | 80 | 70 | 13 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 136 |
Common Stock (Par) | 483 | 482 | 481 | 384 | 0 |
Capital Surplus | 62 | 37 | 18 | 6 | 4 |
Retained Earnings | -333 | -239 | -210 | -103 | -50 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 212 | 280 | 288 | 287 | 90 |
Total Liabilities & Shareholder's Equity | 254 | 364 | 369 | 357 | 103 |
Total Common Equity | 212 | 280 | 288 | 287 | -46 |
Shares Outstanding | 42.10 | 41.90 | 41.70 | 36.70 | NA |
Book Value Per Share | 5.04 | 6.67 | 6.92 | 7.82 | 0.00 |
Fiscal Year End for Repare Therapeutics Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 224 | 250 | 281 | 314 |
Receivables | NA | 15 | 19 | 7 | 7 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 5 | 6 | 4 | 4 |
Total Current Assets | NA | 244 | 275 | 292 | 326 |
Net Property & Equipment | NA | 4 | 5 | 5 | 5 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 2 | 2 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 254 | 286 | 302 | 336 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 2 | 5 | 5 | 4 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 24 | 21 | 22 | 17 |
Income Taxes Payable | NA | 0 | 0 | 0 | 5 |
Other Current Liabilities | NA | 10 | 20 | 24 | 53 |
Total Current Liabilities | NA | 39 | 49 | 53 | 81 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 2 | 2 | 1 | 1 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 42 | 53 | 56 | 85 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 483 | 483 | 483 | 483 |
Capital Surplus | NA | 62 | 56 | 49 | 43 |
Retained Earnings | NA | -333 | -305 | -286 | -274 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 212 | 233 | 245 | 251 |
Total Liabilities & Shareholder's Equity | NA | 254 | 286 | 302 | 336 |
Total Common Equity | 0 | 212 | 233 | 245 | 251 |
Shares Outstanding | 37.00 | 42.10 | 42.00 | 42.00 | 42.00 |
Book Value Per Share | 0.00 | 5.04 | 5.56 | 5.84 | 5.98 |